WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced the presentation of favorable clinical findings with the Company’s IMGN901 targeted anticancer compound at the American Society of Hematology (ASH) 50th Annual Meeting and Exposition being held in San Francisco, CA.
